Overview
Per Sina Finance on October 12, through special sovereign-bond capital injections and shareholder capital increases, 23 insurers have raised over RMB 80bn year-to-date. Beyond insurance SOEs, notable single raises include CMG Primerica Life (RMB 2.656bn), Cathay Lujiazui Life (RMB 2.0bn) and Junlong Life (RMB 1.0bn). Bond issuance is the other main channel: 19 insurers completed or won approval for 21 issues totaling ~RMB 60bn, of which perpetual bonds at RMB 39.9bn—nearly 70%—surpassed traditional capital-supplement bonds in scale for the first time.
The root cause of the capital rush: the C-ROSS Phase II transition period ended at end-2025, and from 2026 stricter capital and risk-measurement rules are fully in force, compounded by new-accounting-standard switches that force larger reserves and pressure solvency ratios. At the industry level, Q2 2026 average comprehensive solvency was 180.6% and core solvency 133.5%—well above regulatory floors—but some small and mid-sized insurers remain near the red line.
Background & Interpretation
1. Regulatory and Industry Context
The C-ROSS II rules, issued end-2021 with a “one-company-one-policy” three-year transition extended to end-2025, became fully binding in 2026. Peking University’s Zhu Junsheng notes minimum capital rose ~5%–8% on average; for P&C firms, higher non-auto risk weights (credit, guarantee, catastrophe) lifted minimum capital ~7.5%.
2. Core Drivers and Mechanisms
New accounting standards add a second pressure: from 2026, unlisted insurers adopt new financial-instrument and insurance-contract standards, discounting reserves at spot rates. With rates low, discounted reserve present values rise, directly hitting net assets. Dividend-insurance transformation and non-auto expansion also demand capital buffers.
3. Market Structure and Value-Chain Impact
Capital replenishment shows a “equity + bond” dual drive; perpetual bonds’ share jump reflects preference for long-duration, undated capital. Yet five insurers remained non-compliant at Q2 (Huahui, Anhua Agri, Changsheng, Qianhai P&C, Yatai P&C), underscoring small-firm urgency. Divergence deepens: leaders are comfortable on capital and risk control, laggards face persistent replenishment pressure.
Implications & Outlook
Near term, the equity and bond windows stay open, with perpetuals likely remaining the mainstream capital tool. Medium term, rigid capital constraints push insurers from scale to capital-efficiency and risk-pricing orientation; new-standard net-asset volatility warrants monitoring.
Takeaways for Industry Participants
- Insurers should coordinate equity and capital instruments to optimize structure and solvency resilience.
- Investors can favor high-dividend, well-capitalized large insurers’ relative strength under tight supervision.
- Reinsurers and rating agencies should embed new-standard net-asset volatility into exposure assessment.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.